JP7582970B2 - Ｗｅｅ１阻害剤化合物の結晶形及びその応用 - Google Patents

Ｗｅｅ１阻害剤化合物の結晶形及びその応用 Download PDF

Info

Publication number
JP7582970B2
JP7582970B2 JP2021564588A JP2021564588A JP7582970B2 JP 7582970 B2 JP7582970 B2 JP 7582970B2 JP 2021564588 A JP2021564588 A JP 2021564588A JP 2021564588 A JP2021564588 A JP 2021564588A JP 7582970 B2 JP7582970 B2 JP 7582970B2
Authority
JP
Japan
Prior art keywords
crystalline form
pattern
compound
formula
angles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021564588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530812A (ja
Inventor
文▲遠▼ ▲銭▼
▲純▼道 ▲楊▼
正▲偉▼ 李
▲ジエ▼ 李
健 黎
曙▲輝▼ ▲陳▼
Original Assignee
ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド filed Critical ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド
Publication of JP2022530812A publication Critical patent/JP2022530812A/ja
Application granted granted Critical
Publication of JP7582970B2 publication Critical patent/JP7582970B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2021564588A 2019-04-30 2020-04-30 Ｗｅｅ１阻害剤化合物の結晶形及びその応用 Active JP7582970B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910364694.X 2019-04-30
CN201910364694 2019-04-30
PCT/CN2020/088451 WO2020221358A1 (zh) 2019-04-30 2020-04-30 Wee1抑制剂化合物的晶型及其应用

Publications (2)

Publication Number Publication Date
JP2022530812A JP2022530812A (ja) 2022-07-01
JP7582970B2 true JP7582970B2 (ja) 2024-11-13

Family

ID=73029676

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021564588A Active JP7582970B2 (ja) 2019-04-30 2020-04-30 Ｗｅｅ１阻害剤化合物の結晶形及びその応用

Country Status (21)

Country Link
US (1) US12291536B2 (enExample)
EP (1) EP3964510B1 (enExample)
JP (1) JP7582970B2 (enExample)
CN (1) CN113784968B (enExample)
AU (1) AU2020266956B2 (enExample)
BR (1) BR112021021230A8 (enExample)
CA (1) CA3138240C (enExample)
DK (1) DK3964510T3 (enExample)
ES (1) ES2984617T3 (enExample)
FI (1) FI3964510T3 (enExample)
HR (1) HRP20241008T1 (enExample)
HU (1) HUE068061T2 (enExample)
IL (1) IL287472A (enExample)
LT (1) LT3964510T (enExample)
PL (1) PL3964510T3 (enExample)
PT (1) PT3964510T (enExample)
RS (1) RS65747B1 (enExample)
SG (1) SG11202111315XA (enExample)
SI (1) SI3964510T1 (enExample)
SM (1) SMT202400303T1 (enExample)
WO (1) WO2020221358A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023217201A2 (zh) * 2022-05-10 2023-11-16 杭州德睿智药科技有限公司 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018171633A1 (zh) 2017-03-23 2018-09-27 上海迪诺医药科技有限公司 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163939B2 (en) * 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
NZ598071A (en) * 2006-10-27 2013-08-30 Signal Pharm Llc Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
EP2155752B1 (en) * 2007-04-25 2018-09-19 Merck Sharp & Dohme Corp. Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor
WO2009054332A1 (ja) 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. ピリドン置換ジヒドロピラゾロピリミジノン誘導体
PL2477628T3 (pl) 2009-09-15 2015-02-27 Merck Sharp & Dohme Wytwarzanie krystalicznych hemihydratowych postaci dihydropirazolopirymidynonu
TWI532742B (zh) 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
EP2731953A1 (en) 2011-07-15 2014-05-21 Abbvie Inc. Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases
US8796289B2 (en) 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
EP2776434A1 (en) 2011-10-20 2014-09-17 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
MX2014010176A (es) 2012-02-23 2014-11-10 Abbvie Inc Inhibidores de cinasas de piridopirimidinona.
GB201306610D0 (en) 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
WO2015019037A1 (en) 2013-08-05 2015-02-12 Almac Discovery Limited Pharmaceutical compounds
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
CA3003737C (en) 2015-11-01 2021-09-14 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of making and using the same
JP7290638B2 (ja) 2017-11-01 2023-06-13 ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド Ｗｅｅ１阻害剤としての大環状化合物及びその使用
EP3875460A4 (en) 2018-10-26 2022-07-20 Wuxi Biocity Biopharmaceutics Co., Ltd. PYRIMIDINDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018171633A1 (zh) 2017-03-23 2018-09-27 上海迪诺医药科技有限公司 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用

Also Published As

Publication number Publication date
US12291536B2 (en) 2025-05-06
PL3964510T3 (pl) 2024-08-19
CA3138240A1 (en) 2020-11-05
AU2020266956A1 (en) 2021-10-28
JP2022530812A (ja) 2022-07-01
HUE068061T2 (hu) 2024-12-28
PT3964510T (pt) 2024-07-29
DK3964510T3 (da) 2024-07-29
ES2984617T3 (es) 2024-10-30
BR112021021230A8 (pt) 2023-04-25
EP3964510A4 (en) 2023-04-26
SG11202111315XA (en) 2021-11-29
IL287472A (en) 2021-12-01
LT3964510T (lt) 2024-08-12
SMT202400303T1 (it) 2024-09-16
HRP20241008T1 (hr) 2024-11-08
RS65747B1 (sr) 2024-08-30
FI3964510T3 (fi) 2024-07-24
BR112021021230A2 (enExample) 2021-12-21
EP3964510A1 (en) 2022-03-09
US20220220120A1 (en) 2022-07-14
EP3964510B1 (en) 2024-07-03
CN113784968A (zh) 2021-12-10
SI3964510T1 (sl) 2024-10-30
CA3138240C (en) 2025-04-01
WO2020221358A1 (zh) 2020-11-05
CN113784968B (zh) 2024-03-15
AU2020266956B2 (en) 2025-05-08

Similar Documents

Publication Publication Date Title
JP7582970B2 (ja) Ｗｅｅ１阻害剤化合物の結晶形及びその応用
JP7573019B2 (ja) Ａｔｒ阻害剤の結晶形及びその使用
EP2985277B1 (en) Method for preparing an atropisomer of a pyrrole derivative
KR20130122612A (ko) 오에스아이 906의 다형체
BR112015017963B1 (pt) Composto de fenil amino pirimidina deuterado, método para preparar a composição farmacêutica, composição farmacêutica e uso do composto
WO2022166994A1 (zh) 一种萘基脲类化合物、其制备方法及应用
US20240391896A1 (en) Small molecule compound targeting bcl9/beta-catenin interaction
JP7282780B2 (ja) ４－（ナフタレン－１－イル）－４ｈ－１，２，４－トリアゾール系化合物の結晶形、塩形態及びその製造方法
CN117355528B (zh) 吡咯并三嗪类化合物的盐型、其晶型及其制备方法
RU2842334C2 (ru) Кристаллическая форма ингибирующего wee1 соединения и ее применение
HK40060045A (en) Crystal form of wee1 inhibitor compound and use thereof
HK40060045B (zh) Wee1抑制剂化合物的晶型及其应用
WO2020224585A1 (zh) 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法
CN114644615B (zh) 一种吲唑类衍生物的结晶形式及其制备方法
RU2832707C2 (ru) Кристаллическая форма ингибитора atr и ее применение
CN110590663A (zh) 一种1，8-萘酰亚胺衍生物及其应用
EP4467536A1 (en) Crystalline form of sulfur-containing isoindoline derivative
HK40074313B (zh) 一种atr抑制剂的晶型及其应用
Hu et al. Design, synthesis and evaluation of novel UDCA-tetrahydropyrazine triazole hybrids for the treatment of pulmonary fibrosis
JP2025510077A (ja) １Ｈ－ピロロ［２，３－ｃ］ピリジン系化合物の結晶形及びその製造方法
HK40074313A (en) Crystalline form of atr inhibitor and use thereof
HK1241358A1 (en) Crystal of (s)-1-(2-hydroxyethyl)-4-methyl-n- [4-(methylsulfonyl)phenyl]-5-[2-(trifluoromethyl)phenyl]- 1h-pyrrole-3-carboxamide
HK1221214B (en) Method for preparing an atropisomer of a pyrrole derivative

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220105

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240904

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241031

R150 Certificate of patent or registration of utility model

Ref document number: 7582970

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150